Caisse DE Depot ET Placement DU Quebec trimmed its holdings in shares of Edwards Lifesciences Corp (NYSE:EW) by 4.1% in the 4th quarter, Holdings Channel reports. The firm owned 25,802 shares of the medical research company’s stock after selling 1,100 shares during the quarter. Caisse DE Depot ET Placement DU Quebec’s holdings in Edwards Lifesciences were worth $2,908,000 at the end of the most recent quarter.

Other large investors have also added to or reduced their stakes in the company. Bank of New York Mellon Corp raised its holdings in shares of Edwards Lifesciences by 45.7% in the fourth quarter. Bank of New York Mellon Corp now owns 7,580,924 shares of the medical research company’s stock valued at $854,444,000 after acquiring an additional 2,377,444 shares in the last quarter. Atlantic Trust Group LLC raised its holdings in shares of Edwards Lifesciences by 734.7% in the third quarter. Atlantic Trust Group LLC now owns 914,989 shares of the medical research company’s stock valued at $100,018,000 after acquiring an additional 805,370 shares in the last quarter. Alliancebernstein L.P. raised its holdings in shares of Edwards Lifesciences by 12.1% in the fourth quarter. Alliancebernstein L.P. now owns 6,259,771 shares of the medical research company’s stock valued at $705,539,000 after acquiring an additional 675,216 shares in the last quarter. Janus Henderson Group PLC raised its holdings in shares of Edwards Lifesciences by 1,135.0% in the third quarter. Janus Henderson Group PLC now owns 619,703 shares of the medical research company’s stock valued at $67,739,000 after acquiring an additional 569,525 shares in the last quarter. Finally, Champlain Investment Partners LLC bought a new stake in shares of Edwards Lifesciences in the fourth quarter valued at about $56,393,000. Institutional investors and hedge funds own 82.86% of the company’s stock.

How to Become a New Pot Stock Millionaire

In other news, CEO Michael A. Mussallem sold 32,800 shares of the business’s stock in a transaction dated Tuesday, December 19th. The stock was sold at an average price of $114.82, for a total transaction of $3,766,096.00. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, VP Donald E. Bobo, Jr. sold 5,300 shares of the business’s stock in a transaction dated Monday, January 29th. The stock was sold at an average price of $127.24, for a total value of $674,372.00. Following the sale, the vice president now owns 24,908 shares in the company, valued at approximately $3,169,293.92. The disclosure for this sale can be found here. Insiders have sold 184,563 shares of company stock worth $22,358,569 in the last 90 days. Insiders own 2.13% of the company’s stock.

Several analysts recently weighed in on the company. Cowen restated a “buy” rating and issued a $150.00 price objective on shares of Edwards Lifesciences in a report on Thursday, February 1st. JMP Securities lifted their price objective on Edwards Lifesciences from $135.00 to $140.00 and gave the company a “market outperform” rating in a report on Friday, February 2nd. Stifel Nicolaus restated a “buy” rating and issued a $155.00 price objective on shares of Edwards Lifesciences in a report on Friday, February 2nd. Morgan Stanley lifted their price objective on Edwards Lifesciences from $130.00 to $138.00 and gave the company an “overweight” rating in a report on Friday, February 2nd. Finally, Guggenheim restated a “buy” rating and issued a $162.00 price objective on shares of Edwards Lifesciences in a report on Friday, February 2nd. Three analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has given a strong buy rating to the stock. The stock currently has an average rating of “Buy” and an average target price of $141.15.

Shares of Edwards Lifesciences Corp (EW) opened at $140.83 on Wednesday. Edwards Lifesciences Corp has a 52 week low of $91.30 and a 52 week high of $141.65. The firm has a market capitalization of $29,580.00, a PE ratio of 34.35, a PEG ratio of 2.06 and a beta of 0.56. The company has a current ratio of 1.80, a quick ratio of 1.41 and a debt-to-equity ratio of 0.15.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings results on Thursday, February 1st. The medical research company reported $0.94 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.91 by $0.03. Edwards Lifesciences had a return on equity of 27.78% and a net margin of 18.11%. The business had revenue of $888.50 million for the quarter, compared to analyst estimates of $868.45 million. During the same quarter in the previous year, the firm earned $0.75 earnings per share. The company’s revenue was up 15.7% on a year-over-year basis. research analysts forecast that Edwards Lifesciences Corp will post 4.49 EPS for the current fiscal year.

Edwards Lifesciences announced that its Board of Directors has authorized a share buyback program on Thursday, December 7th that allows the company to buyback $1.00 billion in outstanding shares. This buyback authorization allows the medical research company to reacquire shares of its stock through open market purchases. Stock buyback programs are typically a sign that the company’s board believes its shares are undervalued.

TRADEMARK VIOLATION NOTICE: This news story was originally reported by Daily Political and is owned by of Daily Political. If you are viewing this news story on another domain, it was copied illegally and republished in violation of US and international trademark & copyright laws. The legal version of this news story can be viewed at https://www.dailypolitical.com/2018/03/14/edwards-lifesciences-corp-ew-shares-sold-by-caisse-de-depot-et-placement-du-quebec.html.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corp (NYSE:EW).

Institutional Ownership by Quarter for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.